Novo Nordisk is already assessing semaglutide’s effects in liver disease linked to obesity — metabolic dysfunction-associated steatohepatitis — but this is the first study to assess the effectiveness of the new generation of weight-loss treatments on alcoholic liver disease, which kills more than 30,000 Americans a year.

Novo Nordisk A/S is dipping a toe into research on whether weight-loss drugs can help people drink less alcohol, a field it’s avoided so far as it concentrates on other conditions.

Novo Nordisk will see if it can expand its weight loss drugs into yet another significant area, that of harms from alcohol consumption.

Novo Nordisk (NVO) plans to run a Phase 2 study to determine whether their weight loss drugs can impact alcohol use in patients with liver disease. Read more here.